La tirzepatida combina GLP-1 + GIP
Lipid profiles, glycemic profiles, and liver function all improved following GLP-1 RA treatment
Publicerades: Fre 13 feb 14:23 I Sverige kan det vara ett brott att sprida uppgifter som kan skada en persons rykte, nmligen frtal
In the SUSTAIN 6 CV outcomes trial (CVOT), once-weekly semaglutide (0.5 or 1.0 mg) added to standard of care significantly reduced the occurrence of a first major adverse CV event (MACE: CV death, nonfatal myocardial infarction [MI], or nonfatal stroke) vs placebo over 2 years in 3297 subjects with T2D and high CV risk [12]
The primary concern is not a direct chemical interaction but rather how acid reduction might affect nutrient absorption and GLP-1 medication performance if you're using an oral formulation
A: Yes, you can change the weekly dose day as long as there are at least 3 days (72 hours) between doses